
FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis
pharmafile | October 7, 2020 | News story | Research and Development, Sales and Marketing | Biogen, Glenmark, generic, multiple sclerosis
Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version of Biogen’s Tecfidera, for the treatment of relapsing multiple sclerosis in adult patients.
Like it’s reference product, the approval is for a delayed-release formulation of the therapy in 120mg and 240mg doses.
The decision could be a significant boon to the company’s finances; according to 12-month IQVIA sales data leading up to the end of August this year, Tecfidera delayed-release capsules generated $3.8 billion in annual sales.
With this decision, Glenmark’s portfolio now spans 164 US-approved products, while a further 46 applications are awaiting review with the FDA. The company said it was committed to supporting the growth of this portfolio through external development partnerships.
Matt Fellows
Related Content

Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …

Sanofi shares results from phase 2 trial for frexalimab in MS treatment
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for …

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …






